133 results about "Hepatic encephalopathy" patented technology

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and / or to develop and monitor the outcome of therapeutic treatments. An exemplary disease / condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

The invention features the use of a defined microbial consortia for the replacement of a gut microbiome associated with disease. In particular, the invention provides for the treatment of hyperammonemia, Clostridium difficile colitis, hepatic encephalopathy associated with cirrhosis, and inflammatory bowel disease.

Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

The invention discloses a traditional Chinese medicine composition for treating acute hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicinal herbs: radix bupleuri, folium isatidis, isatis root, chrysanthemum, taraxacum officinale root, herba violae, pericarpium citri reticulatae viride, rhizoma cyperi, costus root, hawthorn, angelica sinensis, raw rehmannia, radix scrophulariae, root of kudzu vine, radix paeoniae alba, soapstone, cape jasmine, houttuynia cordata, subprostrate sophorae, rhizoma smilacis glabrae, oriental wormwood, indigo naturalis, coptis, rheum officinale, felwort, ash bark, radix sophorae falvescentis, bunge cherry seed, lophatherum gracile, bezoar, antelope's horn, patrinia, lithospermum, moutan bark and root of common peony. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of inappetence, hepatitis B virus, hepatitis B carrier, arcane positive, greasy antiposia, diarrhea, jaundice, hepatic encephalopathy, electrolyte disturbance, encephaledema, cerebral hernia, hepatorenal syndrome, hydroperitoneum, electrolyte disturbance and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible Chinese medicinal herbs specified in National Formulary, the traditional Chinese medicine composition has the advantages of low cost, basic no toxic and side effects, and the like.

Compositions that contain valine as an active ingredient but which are entirely free of other amino acids or substantially free of amino other acids as an active ingredient are used as drugs or foods for treating or ameliorating hepatic diseases, whereupon less side effects are caused than in the conventional regimens of pharmacotherapy and yet the compositions ameliorate, palliate or gain recovery from symptoms and abnormalities that are caused by such hepatic diseases, for example, fever, lassitude, loss of appetite, vomiting stomachache, ascites and pleural effusion, or complications of hepatic disease (not including hepatic encephalopathy).

The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.

Soluble complexes of flumazenil, methods for the preparation thereof, pharmaceutical compositions including same and use of the compositions for alleviating or counteracting the various types of hypersomnia, drowsiness, residual effects associated with the administration of sleep / hypnotic drugs, alcohol intoxication or hepatic encephalopathy.

The invention relates to an ornithine aspartate injection and a preparation method thereof. The injection contains ornithine aspartate, water for injection and acid-base adjusting agent, and has the pH value of 5.2-6.0 and the concentration of 0.01-1g / mL. The ornithine aspartate injection is prepared by dissolving the ornithine aspartate by the water for injection, adjusting the pH value by the acid-base adjusting agent, discoloring by activated carbon, leading the volume to be constant, split charging and sterilizing. The injection can be used for treating hepatic encephalopathy. The injection provided by the invention has the characteristics of being less in impurity content, easy in control of quality, safer in clinical application and the like.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention discloses a rifaximin medicine composition and a preparation method of the rifaximin medicine composition. The rifaximin medicine composition comprises the following ingredients in percentages by mass: 40-60% of rifaximin, 10-50% of microcrystalline cellulose, 1-30% of sodium carboxymethyl starch or sodium carboxymethyl starch, 0.5-6% of silicon dioxide, 0.5-6% of stearic acid and a little amount of aqueous solution of hydroxy propyl cellulose with the mass concentration of 0.5-6%. The medicine composition can be made into tablets and capsules, each dose comprises 550mg of rifaximin respectively, and a coating solution for the preparation is an aqueous solution of opadry with the mass concentration of 5-30%. The invention also provides the preparation method of the rifaximin medicine composition. According to the rifaximin medicine composition and the preparation method of the rifaximin medicine composition disclosed by the invention, the preparation of the medicine composition can be rapidly disintegrated to fully take medicine efficacy, so as to improve the health of a patient suffering from liver cirrhosis recurrent hepatic encephalopathy.

The present invention relates to the cloning and characterization of a human serine / threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and / or in "macromolecular crowding" in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

The invention provides a drug for treatment of blood glucose, dyslipidemia and neurodegenerative diseases and a preparation of the drug. The drug is characterized in that the drug inhibits the activity of an intestinal bacterial BSH enzyme and increases the level of conjugated bile acid in anthe intestinal tract, thus the activity of FXR of bile acid receptors FXR is inhibited, synthesis of liverbile acid is improved, and the level of liver cholesterol and triglyceride is decreased; and the drug comprises amide derivatives form by carboxyl in ursodesoxycholic acid (UDCA) or chenodeoxycholic acid (CDCA) steroid stem nucleus and amidogen in other amino acids in addition except for glycine and taurine, and thus blood glucose, dyslipidemia, fatty liver, hepatic encephalopathy and neurodegenerative diseases such as senile dementia can be treated.

The inventions provide an improved treatment for hepatic encephalopathy characterized by hyperammonemia and / or constipation, comprising the oral administration of polyethylene glycol (PEG) in amounts sufficient to reduce plasma levels of ammonia and / or to alleviate constipation. Preferably, the PEG is administered in combination with lactulose, which provides a palatable composition for the treatment of HE with excellent therapeutic benefits and reduced side effects as compared to lactulose alone.

The invention relates to application of bifidobacterium lactis in prevention and treatment of mental disorder, the bifidobacterium lactis is bifidobacterium lactis BL-11, and the preservation number of the bifidobacterium lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bifidobacterium lactis provided by the invention can be used for improving the intestinal permeability and reducing the levels of LPS and D-lactic acid in blood, so that the effect of preventing and treating mental disorders is achieved, and the mental disorders comprise anxiety, depression, attention deficit hyperactivity disorder, autism, autism, schizophrenia, hepatic encephalopathy, anorexia nervosa, Tourette disease and Escherberg syndrome.

The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.

A compound containing o-naphthalene quinone structure for preparing medicines to prevent and treat hyperammonemia and hepatic encephalopathy is prepared from natural Masonate F through structure reformation and optimization.

The invention discloses application of a rifamycin-nitroimidazole coupling molecule represented in a formula I in inhibition of anaerobic or facultative anaerobic ammonia producing floras in gastrointestinal tracts. The rifamycin-nitroimidazole coupling molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low spontaneous drug resistance frequency and has very good application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant anaerobic bacteria. The formula is as shown in the specification.

The present invention provides a compound amino acid injection with high Fischer rate for curing hepatic encephalopathy, which can rapidly lower the blood ammonia density. The present invention increases the weight parts of three branched amino acid and arginine and reduces the weight parts of sulfur amino acid and ammonia amino acid. The injection provided by the present invention is more conducive to regulating the plasma amino acid spectrum to be normal, increases the density of arginine, stably lowers the level of blood ammonia of the patient and improves the immunity of the organism, thus achieving the aim of rapidly improving the symptom of hepatic encephalopathy and replenishing nutrition. Therefore, the injection of the present invention has higher curing effect in improving hepatic encephalopathy.

The invention discloses application of a rifamycin-quinolizidone dual-target molecule represented in a formula I in inhibition of ammonia producing floras in gastrointestinal tracts. The rifamycin-quinolizidone dual-target molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low drug resistance frequency and has application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant bacterial genera (types). The formula I is as shown in the specification.

Provided are an intestinal environment-improving agent containing as an active ingredient a compound represented by formula [I] or a pharmaceutically acceptable salt thereof, and a novel medicine useful in the prevention or treatment of conditions such as hepatic encephalopathy and uremia.

Embodiments of the invention provide a method and device for processing mortality prediction. The method includes the steps: obtaining the age and detection index parameters of a patient to be predicted, wherein the detection index parameters comprises alkaline phosphatase, glutamyl transpeptidase, and hepatitis B E antigen, whether hepatic encephalopathy occurs, serum sodium, blood coagulation, zymogen activity and the total bilirubin; and inputting the age and the detection index parameter to a preset model; inputting the age and the detection index parameters to a preset model, and taking the output result of the preset model as the mortality prediction result of the patient to be predicted within a preset number of days, wherein the preset model is built based on ANN. The device executes the above method. The method and device for processing mortality prediction can improve the prediction accuracy for mortality, caused by acute-on-chronic liver failure related to viral hepatitis B,of a patient within the preset number of days by taking the output result of the preset model constructed based on ANN as the prediction result of the mortality of the patient to be predicted withinthe preset number of days.

An albumin preparation that prevents onset of hepatic encephalopathy caused by conventional amino acid preparations and enhances an effect of improving the symptoms is provided. The albumin preparation containing amino acids is characterized in that a content of albumin is 0.01 to 1.0 w / v %, a content of plurality of amino acids containing branched amino acid is 5 to 10 w / v %, a content of the branched amino acids is equal to or more than 30 w / w % on the basis of the content of total amino acids and further, the Fischer ratio (branched amino acid / [phenylalanine+tyrosine] (molar ratio)) is equal to or more than 20.

A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

The inventions provide an improved treatment for hepatic encephalopathy characterized by hyperammonemia and / or constipation, comprising the oral administration of polyethylene glycol (PEG) in amounts sufficient to reduce plasma levels of ammonia and / or to alleviate constipation. Preferably, the PEG is administered in combination with lactulose, which provides a palatable composition for the treatment of HE with excellent therapeutic benefits and reduced side effects as compared to lactulose alone.

The invention discloses compound rifaximin nanoemulsion, which is prepared from the following raw materials in percentage by mass: 30 to 45 percent of surfactant, 1 to 10 percent of cosurfactant, 1 to 16 percent of oil phase, 0.1 to 5 percent of rifaximin, 0.025 to 1.25 percent of trimethoprim lactate and the balance of deionized water. The sum of the mass percentage of the raw materials is 100 percent. The compound rifaximin nanoemulsion is applied to acute and chronic intestinal infection, diarrhea syndrome, diarrhea caused by intestinal flora change, hepatic encephalopathy and the like, obviously improves the bioavailability and stability of rifaximin, is quick in response, lasting in effect and high in safety, and has a wide market prospect in the field of medicines.

The object of the present invention is to provide a compound useful as a renal disease preventive and / or therapeutic agent. The inventors of the present invention investigated compounds having a trypsin inhibitory activity, verified that a guanidinobenzoic acid compound has a trypsin inhibitory activity, and achieved the present invention. This guanidinobenzoic acid compound can be used as: a renal disease preventive and / or therapeutic agent that serves as a substitute drug in a low-protein diet regimen; and a preventive and / or therapeutic agent against diseases to which trypsin contributes such as pancreatitis, reflux esophagitis, hepatic encephalopathy, and influenza.

The invention provides a medicine composition for curing hepatic encephalopathy and hepatitis B, belonging to the field of Chinese materia medica prescriptions. The composition comprises the following components in parts by weight: 5-50 parts of rheum officinale, 10-60 parts of roxburgh rose root, 5-30 parts of black soya bean, 20-90 parts of serissa serissoide, 20-100 parts of Salviacavaleriei, 30-150 parts of siphonostegia chinensis, 5-40 parts of pubescent holly root and 10-60 parts of liquorice. In the medicine composition, pathogenesis and symptomatic treatment are taken as the principal thing; the medicine composition has the efficacies of clearing away heat and toxic material, removing dampness through diuresis, cooling blood, eliminating stasis, stop bleeding, eliminating heat and relaxing the bowels, thus achieving the effects of resisting viruses, cooling the blood, reducing bloodammonia, eliminating excreta reserved in bowel, reducing absorption of toxin in intestinal tracts, protecting a liver and a brain, and preventing and curing the encephalopathy and the hepatitis B.